UK Generics Body Opens Rift With Government And Originators Over Rebate Scheme
BGMA Says It Felt Forced To Seek Judicial Review After Exclusion From VPAS Negotiations
Executive Summary
By launching a bid for judicial review of its exclusion from UK negotiations over the VPAS rebate scheme, the BGMA has thrust itself into conflict with the country’s government as well as local R&D-based industry association, the ABPI.
You may also be interested in...
Sandoz’s Saynor Reflects On Industry Challenges
In the third and final part of his exclusive interview with Generics Bulletin, Sandoz CEO Richard Saynor discusses global off-patent industry challenges including antibiotics shortages, PBM behavior in the US and the UK’s VPAS rebate mechanism.
UK Govt Casts Industry Concerns Aside And Confirms Rise In Statutory Scheme Rebate
The UK government is standing its ground on this year’s hike in the statutory pricing scheme rebate, despite industry worries about the impact on companies’ investment decisions.
Biogen: Patients Must Be At Center Of UK Biosimilar Decision Making
The head of biosimilars for Biogen in the UK & Ireland, Jim Porter, sat down with Generics Bulletin to discuss “system challenges and changes that we’re seeing within the UK’s NHS,” as well as Biogen’s own position in what it says is a very important market for the company.